Clinical and Molecular Allergy最新文献

{"title":"Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient.","authors":"Susanna Bormioli,&nbsp;Andrea Matucci,&nbsp;Laura Dies,&nbsp;Francesca Nencini,&nbsp;Francesca Grosso,&nbsp;Enrico Maggi,&nbsp;Alessandra Vultaggio","doi":"10.1186/s12948-019-0109-z","DOIUrl":"https://doi.org/10.1186/s12948-019-0109-z","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab.</p><p><strong>Case presentation: </strong>We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2 months of treatment in regards to skin involvement.</p><p><strong>Conclusions: </strong>In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0109-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37265797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytology and molecular study for GSTP1 effect on asthma Iraqi patients.","authors":"Israa Hussein Hamzah,&nbsp;Farha A Ali Shafi,&nbsp;Sahar A H Al Sharqi,&nbsp;Suaad Almas Brakhas","doi":"10.1186/s12948-019-0108-0","DOIUrl":"https://doi.org/10.1186/s12948-019-0108-0","url":null,"abstract":"<p><strong>Background: </strong>GST belongs to a super family of phase II detoxification enzyme and it plays an important role in preventing the damage that may occur due to reactive water-soluble compounds generated by the association of reactive intermediates with glutathione.</p><p><strong>Method: </strong>In the present study, we analyzed the frequencies of GSTP1 polymorphism among the Iraqi population using PCR-RFLP technique. Fifty samples from bronchial asthma patients and fifty samples from control cases were subjected to conventional PCR and Restriction Fragment Length Polymorphism (RFLP) to detect GSTP1 genotype and measured different parameters together such as IgE, eosinophilic count, WBC, and so forth. Some of the cases were made to undergo sequence analysis and enrolled in NCBI GenBank with accession number (MG657249-MG657258). The GSTP1 polymorphism was determined using PCR and the resultant 176-bp fragment was subjected to RFLP and digested with BsamA1 to recognize the A-G transition at nucleotide.</p><p><strong>Results: </strong>Homozygotes for Ile105 encoding allele resulted in 176-bp fragment found in 62% andVal105 encoding allele had two fragments of 91 and 85 bp in PCR was found in 4% of asthmatic patients. On the other hand, heterozygotes resulted in three fragments of 176, 91 and 85 bp seen in 34% of patients.</p><p><strong>Conclusion: </strong>To the best of the researcher's knowledge, this is the first-of-its-kind report with regards to the role played by GSTP1 polymorphism in bronchial asthma among the Iraqi patients. Though the study outcomes do not support the large role played by GSTP1 gene polymorphism in the evolution of bronchial asthma disorder, future researchers are suggested to investigate more features for many promising results.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2019-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0108-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37057284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps.","authors":"Carlo Cavaliere,&nbsp;Cristoforo Incorvaia,&nbsp;Franco Frati,&nbsp;Daniela Messineo,&nbsp;Mario Ciotti,&nbsp;Antonio Greco,&nbsp;Marco de Vincentiis,&nbsp;Simonetta Masieri","doi":"10.1186/s12948-019-0106-2","DOIUrl":"https://doi.org/10.1186/s12948-019-0106-2","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.</p><p><strong>Case presentation: </strong>The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting.</p><p><strong>Conclusion: </strong>In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction of the nasal obstruction by nasal polyps.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2019-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0106-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36998984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PPI adverse drugs reactions: a retrospective study.","authors":"Marco Casciaro,&nbsp;Michele Navarra,&nbsp;Giuseppina Inferrera,&nbsp;Marta Liotta,&nbsp;Sebastiano Gangemi,&nbsp;Paola Lucia Minciullo","doi":"10.1186/s12948-019-0104-4","DOIUrl":"https://doi.org/10.1186/s12948-019-0104-4","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are drugs capable of blocking the gastric pump H,K-ATPase in order to inhibit gastric acid secretion. Omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole belong to PPIs category. Although PPIs have a good safety profile, allergic reactions to these molecules can occur. The real rate of hypersensitive reactions to PPIs is unknown. The aim of this retrospective study is to evaluate the rate of hypersensitive reactions to PPIs in patients admitted to our Unit between 2008 and 2013 with a history of drug hypersensitivity. From a database of 1229 patients (921 women, 308 men) with adverse drug reaction we extrapolated the data about PPI reactions. Twelve patients (10 female, 2 men) had a positive history for hypersensitive reaction to PPI. Pantoprazole was the most frequently PPI involved. Based on patient personal history in some cases we performed an oral challenge test for an alternative anti-acid drug and none of them had adverse reactions. According to our experience and according to the literature and pharmacovigilance reports, ADR caused by PPIs are ever increasing. Adverse reactions to these drugs are still under-reported; however, considering the frequency of their prescription worldwide, the risk of severe allergic events is low. Further studies are needed to provide clearer data on the real incidence and prevalence about this matter. This should be useful to help physician in choosing the molecule to prescribe and, in case of hypersensitivity, the alternative molecule to test, also considering the possible cross-reactivity.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2019-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0104-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36880322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities are associated with different features of severe asthma.","authors":"Federica Novelli,&nbsp;Elena Bacci,&nbsp;Manuela Latorre,&nbsp;Veronica Seccia,&nbsp;Maria Laura Bartoli,&nbsp;Silvana Cianchetti,&nbsp;Federico Lorenzo Dente,&nbsp;Antonella Di Franco,&nbsp;Alessandro Celi,&nbsp;Pierluigi Paggiaro","doi":"10.1186/s12948-018-0103-x","DOIUrl":"https://doi.org/10.1186/s12948-018-0103-x","url":null,"abstract":"<p><strong>Background: </strong>According to ATS/ERS document on severe asthma (SA), the management of these patients requires the identification and proper treatment of comorbidities, which can influence the control of asthma.</p><p><strong>Methods: </strong>The aim of this study was to assess the independent effect of different comorbidities on clinical, functional and biologic features of SA. Seventy-two patients with SA according to GINA guidelines were examined. We collected demographic data, smoking habit, asthma history, and assessment of comorbidities. Pulmonary function, inflammatory biomarkers, upper airway disease evaluation, asthma control and quality of life were carefully assessed.</p><p><strong>Results: </strong>The mean age of patients was 59.1 years (65.3% female, 5.6% current smokers). Comorbidities with higher prevalence were: chronic rhinosinusitis with or without nasal polyps (CRSwNP or CRSsNP), obesity and gastro-esophageal reflux (GERD), with some overlapping among them. In an univariate analysis comparing patients with single comorbidities with the other ones, asthmatics with CRSwNP had lower lung function and higher sputum eosinophilia; obese asthmatics had worse asthma control and quality of life, and tended to have lower sputum eosinophils; asthmatics with GERD showed worse quality of life. In multivariate analysis, obesity was the only independent factor associated with poor asthma control (OR 4.9), while CRSwNP was the only independent factor associated with airway eosinophilia (OR 16.2). Lower lung function was associated with the male gender and longer duration of asthma (OR 3.9 and 5.1, respectively) and showed a trend for the association with nasal polyps (OR 2.9, p = 0.06).</p><p><strong>Conclusion: </strong>Our study suggests that coexisting comorbidities are associated with different features of SA.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2018-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0103-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36759709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers of atopic dermatitis, allergic rhinitis and bronchial asthma in pediatric patients: correlation with filaggrin, eosinophil major basic protein and immunoglobulin E.","authors":"Zafar Rasheed,&nbsp;Khaled Zedan,&nbsp;Ghada Bin Saif,&nbsp;Ragaa H Salama,&nbsp;Tarek Salem,&nbsp;Ahmed A Ahmed,&nbsp;Alaa Abd El-Moniem,&nbsp;Maha Elkholy,&nbsp;Ahmad A Al Robaee,&nbsp;Abdullateef A Alzolibani","doi":"10.1186/s12948-018-0102-y","DOIUrl":"https://doi.org/10.1186/s12948-018-0102-y","url":null,"abstract":"<p><strong>Background: </strong>Allergic reactions have been implicated as contributions in a number of atopic disorders, including atopic dermatitis (AD), allergic rhinitis (AR) and bronchial asthma (BA). However, the potential for filaggrin protein, eosinophil major basic protein (MBP) and immunoglobulin E (IgE) to elicit allergic response or to contribute to atopic disorders remains largely unexplored in pediatric patients. This study was undertaken to investigate the status and contribution of filaggrin protein, eosinophil MBP and total IgE in pediatric patients with AD, AR and BA.</p><p><strong>Methods: </strong>Sera from 395 pediatric patients of AD, AR or BA with varying levels of disease activity according to the disease activity index and 410 age-matched non-atopic healthy controls were evaluated for serum levels of atopic markers, including filaggrin, eosinophil MBP and IgE.</p><p><strong>Results: </strong>Serum analysis showed that filaggrin levels were remarkably high in pediatric patients with AD, followed by BA and AR, whereas its levels were low in non-atopic pediatric controls. Eosinophil MBP levels in sera of atopic patients were significantly high as compared with their respective controls, but its levels were highest in AR patients, followed by AD and BA. Total IgE in sera of AD patients was markedly high, followed by AR and BA patients, whereas its levels were low in non-atopic pediatric controls. Interestingly, not only was an increased number of subjects positive for filaggrin protein, eosinophil MBP or total IgE, but also their levels were statistically significantly higher among those atopic patients whose disease activity scores were higher as compared with atopic patients with lower disease activity scores.</p><p><strong>Conclusions: </strong>These findings strongly support a role of filaggrin protein, eosinophil MBP and IgE in the onset of allergic reactions in pediatric patients with AD, AR and BA. The data suggest that filaggrin, eosinophil MBP or IgE might be useful in evaluating the progression of AD, AR or BA and in elucidating the mechanisms involved in the pathogenesis of these pediatric disorders.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2018-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0102-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36763007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid desensitization for brentuximab vedotin (Adceteris^®) allergy: a case report.","authors":"Attilio Di Girolamo,&nbsp;Marcello Albanesi,&nbsp;Alessandro Sinisi,&nbsp;Eustachio Nettis,&nbsp;Danilo Di Bona,&nbsp;Maria Filomena Caiaffa,&nbsp;Luigi Macchia","doi":"10.1186/s12948-018-0100-0","DOIUrl":"https://doi.org/10.1186/s12948-018-0100-0","url":null,"abstract":"<p><strong>Background: </strong>Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgG₁ conjugated with monomethyl-auristatin-E. BV targets the CD30⁺ cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30⁺ cells BV exerts its cytotoxic effect via the monomethyl-auristatin-E moiety. So far, accounts on immediate adverse reactions to BV remain anecdotal. Moreover, few reports exist on desensitization for BV.</p><p><strong>Case presentation: </strong>A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead to a partial remission. Thus, a treatment with BV was started. However, during the second BV infusion, he developed generalized urticaria and dyspnea. In order not to discontinue the treatment with BV, we performed a thorough allergological workup and designed a 12-step rapid desensitization protocol. Overall the desensitization procedure was well tolerated and no major adverse reactions occurred.</p><p><strong>Conclusion: </strong>Rapid desensitization is a suitable and safe option in the case of BV allergy and prevents the BV treatment withdrawal.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2018-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0100-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36639645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug induced Kounis syndrome: does oxidative stress play a role?","authors":"Luisa Ricciardi,&nbsp;Fabiana Furci,&nbsp;Marco Casciaro,&nbsp;Eleonora Di Salvo,&nbsp;Mariateresa Cristani,&nbsp;Valeria Tigano,&nbsp;Paola Lucia Minciullo,&nbsp;Sebastiano Gangemi","doi":"10.1186/s12948-018-0099-2","DOIUrl":"https://doi.org/10.1186/s12948-018-0099-2","url":null,"abstract":"<p><strong>Background: </strong>Kounis syndrome (KS) has been described as the coincidental occurrence of acute coronary syndromes during an allergic reaction with cardiac anaphylaxis. It is caused by inflammatory mediators released after exposure to drugs, food, environmental and other triggers. Oxidative stress occurring in various inflammatory disorders causes molecular damage with the production of advanced oxidation products (AOPPs) and advanced glycation end products (AGEs).</p><p><strong>Case presentation: </strong>Markers of oxidative stress were evaluated in a patient who had experienced KS after antibiotic administration in order to investigate the possible role of these molecules in KS. No data, up to now, are available on biomarkers of oxidative stress in patients with drug-induced KS.</p><p><strong>Conclusions: </strong>AOPPs, but not AGEs, were significantly increased in the KS affected patient compared to controls as already reported in mastocytosis affected patients.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0099-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36614016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The involvement of osmolarity in the safety of contrast media.","authors":"Stefania Isola,&nbsp;Fabiana Furci,&nbsp;Sebastiano Gangemi","doi":"10.1186/s12948-018-0097-4","DOIUrl":"https://doi.org/10.1186/s12948-018-0097-4","url":null,"abstract":"<p><strong>Background: </strong>New non-ionic contrast agents, classified into low osmolar agents and iso-osmolar agents, present different biochemical characteristics that may influence the allergic reactions they cause. The aim of our study was to evaluate how osmolarity may affect safety in the use of contrast agents.</p><p><strong>Case presentation: </strong>Six patients with a positive history for reaction to contrast agent were included in this study. Only one patient prick and intradermal skin test was positive. However, in 5 cases, patients presented an immediate reaction after administration of contrast agent that was not IgE mediated.</p><p><strong>Conclusions: </strong>In this study, we focused on iodixanol, an iso-osmolar contrast agent, finding good safety of this product in patients with previous hypersensitivity reactions to contrast agent.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2018-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0097-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36461468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tryptase as a marker of severity of aortic valve stenosis.","authors":"Laura M Losappio,&nbsp;Corrado Mirone,&nbsp;Michel Chevallard,&nbsp;Laura Farioli,&nbsp;Fabrizio De Luca,&nbsp;Elide A Pastorello","doi":"10.1186/s12948-018-0095-6","DOIUrl":"https://doi.org/10.1186/s12948-018-0095-6","url":null,"abstract":"<p><strong>Background: </strong>Severe aortic valve stenosis is one of the most common cause of mortality in adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase. The aim of this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.</p><p><strong>Case presentation: </strong>The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. Within 2 years after, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The tryptase measurements were higher in patients experiencing MACE (10.9, 11.7 and 9.32 ng/ml) than in non-MACE ones (5.69 and 5.58 ng/ml).</p><p><strong>Conclusions: </strong>In patients affected with severe aortic stenosis, baseline serum tryptase may predict occurence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"16 ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2018-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-018-0095-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36386424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}